Research Notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

Margin improvement coming

Monash IVF
3:27pm
February 27, 2025
MVF’s 1H25 result was in line with guidance provided, with NPAT up 5.5% to $15.8m. Short term volatility in industry cycle volumes does not alter our view of the strong structural growth drivers that we think will underpin growth in the IVF industry. We expect MVF to continue to gain market share in Australia, leverage infrastructure and patient management system to drive higher margins and continue to expand in South East Asia, which we think will drive growth in earnings over the next few years. We have lowered our NPAT in line with guidance provided. We have decreased our target price to $1.45 (from $1.50) driven by earnings revisions. ADD retained.

1H inline- EU jettison? Only one piece of the puzzle

Ramsay Health Care
3:27pm
February 27, 2025
1H underlying operating profit was pre-released so unsurprisingly in line, driven by low single digit admissions growth and indexation gains. However, earnings were a mixed bag, with growth in Australia and UK acute hospitals, while Elysium and EU went backwards on going inflationary pressures. While it is a welcome sign “strategic options” are actively being pursued for the EU division, with possible divestment in the air, new management flagged a multi-year transformation is required in remaining business and it continues to run a ruler across all divisions, making it difficult at this early stage to assess if adjustments in operational strategy will have the desired impact. We adjust FY25-27 earnings, with our price target decreasing to A$37.10. Hold.

Things starting to come together

Coles Group
3:27pm
February 27, 2025
COL’s 1H25 result was above expectations with the performance of the core Supermarkets division the key standout. Key positives: COL delivered $157m of Simplify & Save to Invest (SSI) cost savings during the half, taking cumulative savings to ~$400m over the past 18 months; COL invested significantly into resources to take advantage of industrial action that impacted operations at Woolworths (WOW), which yielded an extra $20m in EBIT during the half. Key negatives: Liquor EBIT was below (-12%) our forecast, although the market saw some slight recovery in November and December; Cash realisation at 69% was low due to the timing of payments but should revert to ~100% for the full year. We lift FY25-27F underlying EBIT by between 3-4%. Our target price increases to $20.90 (from $17.95) on the back of updates to earnings estimates and a roll-forward of our model to FY26 forecasts. Hold rating maintained.

Turnaround in full swing

Intelligent Monitoring Group
3:27pm
February 27, 2025
The result was robust with EBITDA +23% YoY and NPATA +41%. Both Australia and NZ delivered organic revenue growth of +6% YoY and +4%, respectively. The company expects this growth to accelerate materially given recent contract wins in ADT Australia with large enterprise customers. Guidance has been re-affirmed for >$38m EBITDA excluding FY25 acquisitions, implying organic earnings growth of at least +24% HoH. We upgrade our EBITDA forecasts to align with new guidance (>$40m including acquisitions). We forecast FY25 and FY26 EPSA growth of +34% and +51%, respectively. IMB is now trading on 5x FY26 PE. This is too cheap given the growth outlook, cash generation potential ($23m tax credits and $7-8m annual interest savings from the re-fi) and balance sheet capacity (1.4x leverage).

Strap yourself for an exciting 2025

Imricor Medical Systems
3:27pm
February 27, 2025
IMR posted its FY24 result which was in line with our forecast on an underlying basis (albeit lower sales were offset by lower costs). IMR finished the period with US$15.7m in cash, a comfortable position to drive operations forward over the coming quarters. FY25 is setting up to be an exciting year with a number of key catalysts to drive investor interest: (first ventricular tachycardia procedure (European trial); Northstar mapping approval (Europe and US); and approval for atrial flutter (in the US). We have reviewed our forecasts revising down FY25/26 by ~10% and upgrading FY27 by 34% reflecting growing sales momentum as more sites come on board and procedures are performed. As a result our DCF valuation has increased to A$2.18 (was A$1.51). Speculative buy recommendation maintained.

JAWS to crack a smile

Mach7 Technologies
3:27pm
February 27, 2025
Stronger result than expected, with better cost controls a positive surprise in the midst of continued investment in people, processes, and tools to drive longer-term operational efficiencies and product offerings. With M7T sitting on the cusp of OpEx coverage purely through subscription revenues, we see the risk/reward opportunity as continuing to improve. Minor changes to our forecasts see the valuation increase modestly to A$1.37 (from A$1.36). We continue to see significant upside potential in the name.

Putting the AI in AI-Media with its ‘Babel Fish’

Ai-Media Technologies
3:27pm
February 27, 2025
AIM’s 1H25 result was very broadly in line with our expectations and included a reiteration of FY25 guidance and long-term targets. Technically FY25 EBITDA is expected to be flat YoY but it’s a tale of two halves with 2H25 EBITDA of ~$3m up 4x on 1H25 EBITDA of $0.7m and up 45% YoY. Overall, the lead indicators in this result position AIM well to deliver impressive AI power growth and we see significant upside upon execution.

Record 1H25 deployment underpins growth for FY25

Qualitas
3:27pm
February 27, 2025
QAL delivered a solid 1H25 result in line with both our expectations and those of consensus, while the company also reaffirmed full year guidance. 1H25 saw record deployment of $2.4bn, up by 34% on the pcp, with both committed FUM and fee earning FUM booking solid growth. Net funds management revenue, the highest multiple part of the business, registered 20% growth vs pcp beating both our expectations (+12%) and consensus (+8%), having nearly doubled since the Dec-21 IPO – despite this the share price remains broadly in line with the issue price of $2.50/sh. We reiterate our Add recommendation with a $3.35/sh price target (previously $3.20/sh).

Pretty clean

Tyro Payments
3:27pm
February 27, 2025
TYR’s 1H25 EBITDA (~A$33m) was +21% on the pcp, and slightly above consensus (A$32m), whilst 1H25 Normalised NPAT (A$11m, +100% on the pcp) was in line with consensus. We would describe this as a broadly solid result that met expectations in most key areas. The main positive was continued expansion in the EBITDA margin, whilst the key negative was soft top-line growth overall. We downgrade our TYR FY25 EPS by 8% on higher D&A charges, but slightly lift FY26F EPS by 1% on improved margin forecasts. Our target price is set at A$1.60 (previously A$1.51) on earnings changes and a valuation roll-forward. In our view, the turnaround at TYR in the last few years has been significantly underappreciated by the market, and we maintain our ADD call with the stock trading well below our target price.

Delivering in a challenging environment

Worley
3:27pm
February 26, 2025
WOR’s 1H25 result was broadly in-line with MorgF and consensus, with EBITA of $373.4m (+9.0% YoY), driven by Aggregate revenue growth +6.8% and EBITA Margin (Ex. Procurement) expansion of +91bps yoy to 8.4% (steady vs. 2H24). Alongside the result, WOR launched a much welcomed $500m Buyback, further extending its capital management and investment program. FY25 Guidance for low-double digit EBITA growth, and EBITA margins (ex. Procurement) to improve ~8.0-8.5% was reiterated. We make no material changes to our forecasts. Adjusting for time creep in our valuation we retain our Add rating, with a $17.70/sh (prev. $17.40/sh)

News & Insights

Michael Knox, Chief Economist, reveals how the OECD and RBA’s outdated assumptions about global trade fail to account for China’s Marxist-Leninist economic strategies.

This morning, I was asked to discuss Sarah Hunter’s presentation from yesterday. Sarah, the Assistant Governor and Chief Economist at the Reserve Bank of Australia (RBA), delivered a detailed and competent discussion on the conventional view of tariffs’ impact on the international economy. She highlighted that tariffs typically increase inflation and reduce economic output, a perspective echoed by the OECD in a similar presentation overnight. Sarah’s analysis focused on the potential shocks tariffs could cause, particularly their effects on GDP and inflation.

Drawing on my experience as an Australian trade commissioner and my work in Australian embassies, I found her presentation particularly interesting. My background allowed me to bring specialist knowledge to the conversation, which I believe gave me an edge. Notably, I observed that the RBA seems to lack analysts closely tracking individual policymakers in the Trump administration, such as Scott Bessent, whose views on tariffs and competition differ from the general assumptions. The conventional view assumes a world of perfectly competitive countries adhering to international trade rules and unlikely to engage in conflict—a scenario that doesn’t align with the current global trade environment, especially between China and the United States.

China, operating as a Marxist-Leninist economy, aims to dominate global markets by building monopolies in areas like rare earths, nickel, copper, and other base metals. It maintains a managed exchange rate, despite promises to the International Monetary Fund for a freely floating currency. If China allowed its currency, the RMB, to float, it would likely appreciate significantly, increasing imports and reducing its trade surplus. This would create a more balanced international trade environment, potentially reducing the need for other countries to impose tariffs. However, major institutions like the OECD and RBA seem to misjudge the nature of this trade shock, relying on outdated assumptions about global trade dynamics.

The international community also appears to overlook specific U.S. policy intentions, such as those articulated by figures like Peter Navarro and Scott Bessent. The U.S. aims to use tariffs selectively to bolster industries like pharmaceuticals, precision manufacturing, and motor vehicles. This misunderstanding leads public institutions to perceive unspecified risks, as reflected in Sarah’s otherwise able presentation. Because the RBA and similar institutions view the world as fraught with undefined risks, they are inclined to keep interest rates low, responding to perceived threats rather than an equilibrium model.

Interestingly, data from the U.S. economy contradicts the expected negative impacts of tariffs. The Chicago Fed National Activity Indicator, a reliable gauge of economic growth since the 2008 financial crisis, shows U.S. growth above the long-term trend for the first four months of this year. This suggests resilience despite tariff-related shocks. Ideally, growth will slow later this year, prompting the Federal Reserve to cut rates, facilitating a soft landing and a decline in the U.S. dollar to boost global commodity prices. However, this nuanced outlook wasn’t evident in yesterday’s presentation.

Moreover, the anticipated rise in U.S. inflation due to tariffs isn’t materialising. Scott Bessent recently noted that U.S. CPI inflation is lower than expected, with core inflation shown as the (16% trimmed mean) at 3% for the past two months . Core inflation  excluding  food and energy CPI  is only at 2.8%. This suggests that Chinese suppliers are absorbing tariff costs to maintain market share, rather than passing them on as higher prices. Recent Chinese data supports this, showing a slight decline in manufacturing confidence and coal consumption, indicating reduced factory output and electricity use. This points to a modest slowdown in China’s economy. So far the expected negative effects on U.S. prices and output are not occurring.

In summary, the fears expressed by institutions like the RBA and OECD about the Trump administration’s trade policies appear overstated. The U.S. economy is not experiencing the predicted declines in output or increases in inflation. While these effects may emerge later, the current data suggests that the risks are not as severe as anticipated, highlighting a disconnect between theoretical models and real-world outcomes.

Read more
Michael Knox outlines the economic outlook for growth and inflation in the U.S., the Euro area, China, India, and Australia, drawing data from the International Monetary Fund, the Congressional Budget Office, European sources, and his own analysis for Australia.

Today, I’m presenting the first page of my updated presentation, which focuses on GDP growth and inflation expectations for major economies. Before diving into that, I want to clarify a point about U.S. trade negotiations that has confused some media outlets.

In the previous Trump Administration ,there was single trade negotiator, Robert Lighthizer, held a cabinet position with the rank of Ambassador. This time, to expedite negotiations and give them more weight, Trump has appointed two additional cabinet-level officials to handle trade talks with different regions. For Asian economies, Scott Bessent and Ambassador Jamison Greer, who succeeded Lighthizer and previously served on the White House staff, are managing negotiations, including those with China. For Europe, Howard Lutnick, the Commerce Secretary, and Ambassador Greer are negotiating with the European Trade Representative. When the EU representative visits Washington, D.C., they meet with Lutnick and Greer, while Chinese or Japanese representatives engage with Bessent and Greer.

In my presentation today, I’m outlining the economic outlook for growth and inflation in the U.S., the Euro area, China, India, and Australia, drawing data from the International Monetary Fund, the Congressional Budget Office, European sources, and my own analysis for Australia.

For the U.S., the best-case scenario is a soft landing, with growth slowing but remaining positive at 1.3% this year and rising to 1.7% next year. This slowdown allows the Federal Reserve to continue cutting interest rates, leading to a decline in the U.S. dollar. This in turn ,triggers a recovery in commodity prices. These prices have stabilized and are now trending upward, with an expected acceleration as the dollar weakens.

U.S. headline inflation is projected to be just below 3% next year, with higher figures this year driven by tariff effects.



Global Economic Perspective

In the Euro area, growth is accelerating slightly, from just under 1% this year to 1.2% next year, with inflation expected to hit the 2% target this year and dip to 1.9% next year.

China’s GDP growth is forecast  at 4% for both this year and next, a step down from previous 5% rates, reflecting a significant slump in domestic demand and very low inflation  Chinese Inflation is only  :   0.2% last year, 0.4% this year, and 0.9% next year.  Despite a massive fiscal push, with a budget deficit around 8% of GDP, China’s debt-to-GDP ratio is rising faster than the U.S.. Yet this is  yielding more modest  domestic growth.

India, on the other hand, continues to outperform, with 6.5% GDP growth last year, 6.2% this year, and  6.3%  next year, surpassing earlier projections.

Read more
In our International Reporting Season Review, we provide an overview of the March 2025 quarterly results season for companies in the Americas, Europe and Asia.

Positive earnings surprise

In our International Reporting Season Review, we provide an overview of the March 2025 quarterly results season for companies in the Americas, Europe and Asia. For all the volatility in markets caused by US trade policy, the results were positive. For all the 187 high profile and blue-chip companies in our International Watchlist, the median EPS beat vs consensus was 3.2%, nearly twice that recorded in the December quarter (1.8%). 37% of companies exceeded consensus EPS expectations by more than 5% and only 9% missed by more than 5%. Communication Services was the most positive sector, led by Magnificent 7 companies Alphabet and Meta Platforms. The median EPS beat in that sector was 13%. Consumer Discretionary was the biggest disappointment (though only a mild one) with EPS falling 0.6% short of analyst estimates on a median basis.

Alphabet and Meta among the best performers

Across our Watchlist, some of the best performing stocks in terms of EPS beats were Alphabet, Boeing, Uniqlo-owner Fast Retailing, Meta Platforms, Newmont and The Walt Disney Company. Notable misses came from insurance broker Aon, BP, PepsiCo, Starbucks, Tesla and UnitedHealth. The latter saw by far the worst share price performance over reporting season, its earnings weakness compounded by the resignation of its CEO and the launch of a fraud investigation by the Department of Justice. British luxury fashion label Burberry had the best performing share price as it gains traction in its turnaround plan.

Tariffs were the main talking point (of course)

The timing of President Trump’s ‘Liberation Day’ on 2 April, just before the March quarter results started rolling in, guaranteed that US tariffs would be the main talking point throughout reporting season. Most companies took the line that higher tariffs presented a material risk to global growth and inflation. The rapidly shifting sands of US trade policy mean the impact of tariffs is highly uncertain. This didn’t stop many companies from trying to estimate the impact on their profits. This ranged from the very precise ($850m said RTX) to the extremely vague (‘a few hundred million dollars’ hazarded Abbott Laboratories). The rehabilitation of AI as a systemic driver of long-term value was a key theme of reporting season, with many companies reporting what Palantir Technologies described as an ‘unstoppable whirlwind of demand’ and others indicating an increase in planned AI investment. The deterioration in consumer confidence was another key talking point, though most companies could only express concern about a possible future softening in demand rather than any actual evidence of a hit to sales.

Our International Focus List continues to outperform

In this report, we also report on the performance of the Morgans International Focus List, which is now up 25.3% since inception last year, outperforming the benchmark S&P 500 by 20.4%.


Morgans clients receive exclusive insights such as access to our latest International Reporting Season article.

Contact us today to begin your journey with Morgans.

      
Contact us
      
      
Find an adviser
      
Read more